Statements (68)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:accessories |
gptkb:CORBA
various governments |
| gptkbp:approves |
gptkb:WHO
gptkb:EMA UK Medicines and Healthcare products Regulatory Agency FDA (under review) |
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:booster_recommendation |
after 6 months
|
| gptkbp:clinical_trial |
over 30,000
Phase III trials Phase II/ III |
| gptkbp:developed_by |
gptkb:Astra_Zeneca
|
| gptkbp:distribution |
global
|
| gptkbp:dosage_form |
2
|
| gptkbp:emergency_services |
multiple countries
|
| gptkbp:first_dose |
initial dose
|
| https://www.w3.org/2000/01/rdf-schema#label |
Astra Zeneca vaccine
|
| gptkbp:is_effective_against |
approximately 76%
about 76% effective |
| gptkbp:is_vulnerable_to |
December 2020
varies by country intramuscular injection ongoing studies adverse event reporting mixed responses public and private sectors logistical issues reduces transmission against variants non-replicating viral vector stable at refrigerator temperatures viral vector platform contributes to herd immunity against severe disease against hospitalization against symptomatic infection requires cold chain complex logistics reduces severity of illness |
| gptkbp:manufacturer |
multiple countries
|
| gptkbp:name |
gptkb:Vaxzevria
|
| gptkbp:partnerships |
gptkb:Oxford_University
|
| gptkbp:safety_measures |
ongoing
|
| gptkbp:second_dose |
booster dose
|
| gptkbp:side_effect |
fatigue
headache muscle pain nausea fever thrombosis thrombocytopenia |
| gptkbp:target_audience |
adults
elderly |
| gptkbp:targets |
gptkb:COVID-19
SARS-Co V-2 virus |
| gptkbp:type |
viral vector vaccine
|
| gptkbp:uses |
viral vector technology
|
| gptkbp:uses_technology |
recombinant DNA technology
|
| gptkbp:vaccine_clinical_data |
peer-reviewed publications
|
| gptkbp:vaccine_collaboration |
international partnerships
|
| gptkbp:vaccine_ethical_considerations |
equitable access
|
| gptkbp:vaccine_global_access |
affordable pricing
|
| gptkbp:vaccine_public_health_role |
critical in pandemic response
|
| gptkbp:vaccine_regulatory_status |
authorized for emergency use
|
| gptkbp:vaccine_research_focus |
long-term immunity
|
| gptkbp:bfsParent |
gptkb:vaccine
|
| gptkbp:bfsLayer |
4
|